Cedric received his Ph.D in Oncology from the University of Toulouse, France where he studied mechanisms underlying the PI3K/Akt and mTOR pathways activation in Acute Myeloid Leukemia. He did his post-doctoral training at City of Hope, Duarte, CA with Dr. Ravi Bhatia and Dr. Steve Forman assessing the impact of small molecules and immunotherapy (CAR-T) on AML stem/progenitor cells maintenance and drug resistance. After his training he joined the University of Pennsylvania and continued to work on AML and immunotherapy. Cedric joined Amgen and the Clinical Biomarkers and Diagnostics group in June 2015 where he rapidly became the Therapeutic Area lead for all Immuno-Oncology programs (BiTE® and CAR-T) at Amgen within the Leukemia and Lymphoma space including the first FDA approved BiTE® Blincyto®. Cedric recently took more responsibility and he is now responsible for the Heme/Onc pipeline and Clinical Biomarker strategy at Amgen.